161 related articles for article (PubMed ID: 35305599)
21. Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses.
Sun L; Pennells L; Kaptoge S; Nelson CP; Ritchie SC; Abraham G; Arnold M; Bell S; Bolton T; Burgess S; Dudbridge F; Guo Q; Sofianopoulou E; Stevens D; Thompson JR; Butterworth AS; Wood A; Danesh J; Samani NJ; Inouye M; Di Angelantonio E
PLoS Med; 2021 Jan; 18(1):e1003498. PubMed ID: 33444330
[TBL] [Abstract][Full Text] [Related]
22. Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.
Schmucker C; Eisele-Metzger A; Meerpohl JJ; Lehane C; Kuellenberg de Gaudry D; Lohner S; Schwingshackl L
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD013556. PubMed ID: 35199850
[TBL] [Abstract][Full Text] [Related]
23. Performance of Cardiovascular Risk Prediction Models Among People Living With HIV: A Systematic Review and Meta-analysis.
Soares C; Kwok M; Boucher KA; Haji M; Echouffo-Tcheugui JB; Longenecker CT; Bloomfield GS; Ross D; Jutkowtiz E; Sullivan JL; Rudolph JL; Wu WC; Erqou S
JAMA Cardiol; 2023 Feb; 8(2):139-149. PubMed ID: 36576812
[TBL] [Abstract][Full Text] [Related]
24. Distribution of 10-year and lifetime predicted risk for cardiovascular disease prior to surgery in the longitudinal assessment of bariatric surgery-2 study.
Mackey RH; Belle SH; Courcoulas AP; Dakin GF; Deveney CW; Flum DR; Garcia L; King WC; Kuller LH; Mitchell JE; Pomp A; Pories WJ; Wolfe BM;
Am J Cardiol; 2012 Oct; 110(8):1130-7. PubMed ID: 22742719
[TBL] [Abstract][Full Text] [Related]
25. Time to improve statin prescription guidelines in low-risk patients?
Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Nonblood-Based and Blood-Based Total CV Risk Scores in Global Populations.
Gaziano TA; Abrahams-Gessel S; Alam S; Alam D; Ali M; Bloomfield G; Carrillo-Larco RM; Dorairaj P; Gutierrez L; Irazola V; Levitt NS; Miranda JJ; Bernabe-Ortiz A; Pandya A; Rubinstein A; Steyn K; Xavier D; Yan LL
Glob Heart; 2016 Mar; 11(1):37-46.e2. PubMed ID: 27102021
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease.
Ofori S; Dodiyi-Manuel S; Akpa MR
J Clin Lipidol; 2017; 11(6):1441-1447. PubMed ID: 29050979
[TBL] [Abstract][Full Text] [Related]
28. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
[TBL] [Abstract][Full Text] [Related]
29. The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study.
Hadaegh F; Asgari S; Moosaie F; Orangi M; Sarvghadi F; Khalili D; Azizi F
J Transl Med; 2021 Jan; 19(1):25. PubMed ID: 33407576
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of hypertension and cardiovascular risk factors among long-term AIDS survivors: A report from the field.
Pierre S; Seo G; Rivera VR; Walsh KF; Victor JJ; Charles B; Julmiste G; Dumont E; Apollon A; Cadet M; Saint-Vil A; Marcelin A; Severe P; Lee MH; Kingery J; Koenig S; Fitzgerald D; Pape J; McNairy ML
J Clin Hypertens (Greenwich); 2019 Oct; 21(10):1558-1566. PubMed ID: 31448551
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort.
Bai JW; Boulet G; Halpern EM; Lovblom LE; Eldelekli D; Keenan HA; Brent M; Paul N; Bril V; Cherney DZ; Weisman A; Perkins BA
Cardiovasc Diabetol; 2016 Jan; 15():14. PubMed ID: 26809442
[TBL] [Abstract][Full Text] [Related]
32. Population-Based Epidemiology of Heart Failure in a Low-Income Country: The Haiti Cardiovascular Disease Cohort.
Kingery JR; Roberts NL; Lookens Pierre J; Sufra R; Dade E; Rouzier V; Malebranche R; Theard M; Goyal P; Pirmohamed A; Yan LD; Hee Lee M; Nash D; Metz M; Peck RN; Safford MM; Fitzgerald D; Deschamps MM; Pape JW; McNairy M
Circ Cardiovasc Qual Outcomes; 2023 Feb; 16(2):e009093. PubMed ID: 36472189
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular disease risk profile and management practices in 45 low-income and middle-income countries: A cross-sectional study of nationally representative individual-level survey data.
Peiris D; Ghosh A; Manne-Goehler J; Jaacks LM; Theilmann M; Marcus ME; Zhumadilov Z; Tsabedze L; Supiyev A; Silver BK; Sibai AM; Norov B; Mayige MT; Martins JS; Lunet N; Labadarios D; Jorgensen JMA; Houehanou C; Guwatudde D; Gurung MS; Damasceno A; Aryal KK; Andall-Brereton G; Agoudavi K; McKenzie B; Webster J; Atun R; Bärnighausen T; Vollmer S; Davies JI; Geldsetzer P
PLoS Med; 2021 Mar; 18(3):e1003485. PubMed ID: 33661979
[TBL] [Abstract][Full Text] [Related]
34. Comparative performance of pooled cohort equations and Framingham risk scores in cardiovascular disease risk classification in a slum setting in Nairobi Kenya.
Wekesah FM; Mutua MK; Boateng D; Grobbee DE; Asiki G; Kyobutungi CK; Klipstein-Grobusch K
Int J Cardiol Heart Vasc; 2020 Jun; 28():100521. PubMed ID: 32373711
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and factors associated with lipid-lowering medications use for primary and secondary prevention of cardiovascular diseases among Malaysians: the REDISCOVER study.
Baharudin N; Mohamed-Yassin MS; Daher AM; Ramli AS; Khan NMN; Abdul-Razak S
BMC Public Health; 2022 Feb; 22(1):228. PubMed ID: 35120488
[TBL] [Abstract][Full Text] [Related]
36. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis.
Damen JA; Pajouheshnia R; Heus P; Moons KGM; Reitsma JB; Scholten RJPM; Hooft L; Debray TPA
BMC Med; 2019 Jun; 17(1):109. PubMed ID: 31189462
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular risk assessment in patients with antiphospholipid syndrome: a cross-sectional performance analysis of nine clinical risk prediction tools.
Drosos GC; Konstantonis G; Sfikakis PP; Tektonidou MG
RMD Open; 2023 Nov; 9(4):. PubMed ID: 38016710
[TBL] [Abstract][Full Text] [Related]
38. Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index.
Khera R; Pandey A; Ayers CR; Carnethon MR; Greenland P; Ndumele CE; Nambi V; Seliger SL; Chaves PHM; Safford MM; Cushman M; Xanthakis V; Vasan RS; Mentz RJ; Correa A; Lloyd-Jones DM; Berry JD; de Lemos JA; Neeland IJ
JAMA Netw Open; 2020 Oct; 3(10):e2023242. PubMed ID: 33119108
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular Disease Risk Prediction in the HIV Outpatient Study.
Thompson-Paul AM; Lichtenstein KA; Armon C; Palella FJ; Skarbinski J; Chmiel JS; Hart R; Wei SC; Loustalot F; Brooks JT; Buchacz K
Clin Infect Dis; 2016 Dec; 63(11):1508-1516. PubMed ID: 27613562
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
